20/20 Biolabs, Inc. Common Stock (AIDX) - Total Assets
Based on the latest financial reports, 20/20 Biolabs, Inc. Common Stock (AIDX) holds total assets worth $3.24 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See 20/20 Biolabs, Inc. Common Stock net assets for net asset value and shareholders' equity analysis.
20/20 Biolabs, Inc. Common Stock - Total Assets Trend (2016–2024)
This chart illustrates how 20/20 Biolabs, Inc. Common Stock's total assets have evolved over time, based on quarterly financial data.
20/20 Biolabs, Inc. Common Stock - Asset Composition Analysis
Current Asset Composition (December 2024)
20/20 Biolabs, Inc. Common Stock's total assets of $3.24 Million consist of 56.3% current assets and 43.7% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 49.4% |
| Accounts Receivable | $135.27K | 3.7% |
| Inventory | $47.16K | 1.3% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $499.17K | 13.8% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2016–2024)
This chart illustrates how 20/20 Biolabs, Inc. Common Stock's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see 20/20 Biolabs, Inc. Common Stock market cap and net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: 20/20 Biolabs, Inc. Common Stock's current assets represent 56.3% of total assets in 2024, a decrease from 80.7% in 2016.
- Cash Position: Cash and equivalents constituted 49.4% of total assets in 2024, down from 73.0% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 13.0% of total assets, unchanged from 13.0% in 2016.
- Asset Diversification: The largest asset category is intangible assets at 13.8% of total assets.
20/20 Biolabs, Inc. Common Stock Competitors by Total Assets
Key competitors of 20/20 Biolabs, Inc. Common Stock based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
INKON Life Technology Co Ltd
SHE:300143
|
China | CN¥4.15 Billion |
|
CareRay Digital Medical Technology Co Ltd
SHG:688607
|
China | CN¥988.48 Million |
|
Senseonics Holdings, Inc. Common Stock
NYSE MKT:SENS
|
USA | $139.92 Million |
|
Universus Photo Imagings Limited
NSE:UNIVPHOTO
|
India | Rs8.57 Billion |
|
HansBiomed Corporation
KQ:042520
|
Korea | ₩126.41 Billion |
|
Aligned Genetics Inc
KQ:238120
|
Korea | ₩45.11 Billion |
|
Heramed Ltd
AU:HMD
|
Australia | AU$1.04 Million |
|
Acarix A/S
ST:ACARIX
|
Sweden | Skr48.33 Million |
20/20 Biolabs, Inc. Common Stock - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.79 | 5.89 | 5.89 |
| Quick Ratio | 0.76 | 5.82 | 5.82 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-426.38K | $7.06 Million | $7.06 Million |
20/20 Biolabs, Inc. Common Stock - Advanced Valuation Insights
This section examines the relationship between 20/20 Biolabs, Inc. Common Stock's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 472.77 |
| Latest Market Cap to Assets Ratio | 4.44 |
| Asset Growth Rate (YoY) | -43.3% |
| Total Assets | $3.61 Million |
| Market Capitalization | $16.04 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values 20/20 Biolabs, Inc. Common Stock's assets at a significant premium (4.44x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: 20/20 Biolabs, Inc. Common Stock's assets decreased by 43.3% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for 20/20 Biolabs, Inc. Common Stock (2016–2024)
The table below shows the annual total assets of 20/20 Biolabs, Inc. Common Stock from 2016 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $3.61 Million | -43.26% |
| 2023-12-31 | $6.37 Million | -47.87% |
| 2022-12-31 | $12.22 Million | +18.91% |
| 2021-12-31 | $10.27 Million | +119.62% |
| 2020-12-31 | $4.68 Million | +49.63% |
| 2019-12-31 | $3.13 Million | -23.86% |
| 2018-12-31 | $4.11 Million | +188.67% |
| 2017-12-31 | $1.42 Million | +5.63% |
| 2016-12-31 | $1.35 Million | -- |
About 20/20 Biolabs, Inc. Common Stock
20/20 GeneSystems, Inc. operates as a clinical laboratory testing company focused on cancer screening and viral testing services. The company provides multi-cancer early detection blood testing, including a test called OneTest, and offers viral testing services such as rapid COVID-19 test kits, including the Assure COVID-19 IgG/IgM rapid test. It operates the Clinical Lab Innovation Axcelerator (… Read more